Life Sciences

  • April 03, 2026

    SEC Moves To Set Up $40M Investor Fund In Cassava Case

    The U.S. Securities and Exchange Commission asked a Texas federal court on Friday to establish a $40 million fund to potentially compensate investors harmed by a Texas biopharmaceutical company and two former executives' alleged misstatements about an Alzheimer's drug, following the company's 2024 settlement with the regulator.

  • April 03, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    State lawmakers in Delaware and West Virginia advanced legislation to more tightly regulate kratom products, Missouri and Kentucky legislators considered bills to fund research into the therapeutic uses of the psychedelic ibogaine, and Idaho's Legislature came together to urge voters to reject a medical marijuana legalization proposal that could be on the ballot this November. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • April 03, 2026

    EPA Eyes Microplastics, Drugs For Drinking Water Watch List

    The U.S. Environmental Protection Agency is looking to include microplastics and pharmaceuticals in its drinking water contaminants list for the first time, the agency has announced in a move it says could make the proposed contaminants a consideration in regulatory action.

  • April 03, 2026

    Law360 Announces The Members Of Its 2026 Editorial Boards

    Law360 is pleased to announce the formation of its 2026 Editorial Advisory Boards.

  • April 03, 2026

    Aetna Escapes COVID Testing Payment Suit In Calif.

    A Nebraska testing laboratory failed to prove that Aetna underpaid more than $53 million for COVID-19 testing services, a California federal judge has ruled, dismissing the lab's federal racketeering and state law claims against the insurer but leaving the door open to an amended suit. 

  • April 03, 2026

    NYC Fights Sanctions Over Discovery In IVF Sex Bias Dispute

    New York City urged a federal judge to reject a gay couple's sanctions bid in their suit claiming a municipal health plan blocked them from receiving in vitro fertilization coverage out of discrimination, calling their concerns with the city's sluggish discovery production in the case premature.

  • April 03, 2026

    Caterpillar Worker's Bankruptcy Dooms Genetic Privacy Claim

    An Illinois federal judge has thrown out a Caterpillar Inc. employee's proposed class genetic privacy suit over allegedly illegal medical history probes, saying the worker's midcase Chapter 7 bankruptcy filing means the claims now belong to his bankruptcy estate and not to him personally.

  • April 02, 2026

    Georgia Midwifery Laws Violate State Constitution, Suit Says

    A trio of midwives are challenging Georgia laws that restrict their ability to practice, arguing that the statutes exacerbate an ongoing maternal health crisis and conflict with the Peach State's constitution. 

  • April 02, 2026

    Squires Gives Go-Ahead To 5 Patent Reviews, Denies 8

    In the latest order summarizing his decisions on requests for America Invents Act patent reviews, U.S. Patent and Trademark Office Director John Squires has granted five petitions and turned down eight others.

  • April 02, 2026

    Petition To Repeal Legal Pot Mobilizes A Showdown In Mass.

    A campaign to repeal the legalization of retail cannabis in Massachusetts via ballot initiative — the first campaign of its kind in the country — is uniting legalization advocates, entrepreneurs and industry players in a coordinated response to defeat the effort before it spreads to other states.

  • April 02, 2026

    Ex-Pharma Exec Hit With $5.3M Fee Award In Del.

    The Delaware Chancery Court has ordered a former pharmaceutical executive to pay more than $5.3 million in attorney fees following years of litigation over alleged disloyal conduct and trade secret misuse, concluding that the award is reasonable despite objections that the amount was excessive.

  • April 02, 2026

    Alexion Beats Trade Secret Claims In Amyndas Suit

    Amyndas Pharmaceuticals failed to specifically identify the trade secrets it claimed pharmaceutical company Alexion learned of during early partnership talks and improperly used to launch a business collaboration with another competitor, a Massachusetts federal judge has found.

  • April 02, 2026

    Trump Orders 100% Pharma Tariff, Modifies Metals Duties

    Later this year, the U.S. will impose 100% tariffs on imported pharmaceuticals, but drug companies could qualify for reduced tariff rates as low as zero if they agree to invest domestically and enter most-favored-nation drug-pricing agreements with the government, according to an executive order President Donald Trump signed Thursday.

  • April 02, 2026

    Snell & Wilmer Names Life Sciences Pro As San Diego Leader

    Snell & Wilmer LLP has tapped a longtime corporate attorney who specializes in the life sciences industry to be the new head of its San Diego office.

  • April 02, 2026

    Teva $35M Delayed Generic Inhalers Deal Gets Initial OK

    A Massachusetts federal judge Thursday granted initial approval to a $35 million deal that Teva Pharmaceuticals agreed to pay to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers.

  • April 02, 2026

    Vape Sellers, Makers Evade Ga. Woman's RICO Scheme Suit

    A Georgia federal judge has tossed a suit against numerous vape sellers and makers alleging they conspired to sell vapes with illegal levels of delta-9 THC, saying her complaint fails to allege any kind of scheme, but rather amounts to describing the normal supply chain.

  • April 01, 2026

    Ex-Wilson Sonsini M&A Co-Head Rejoins Goodwin In SF

    A former partner at Goodwin Procter LLP's Silicon Valley office has rejoined the firm in San Francisco after co-leading Wilson Sonsini Goodrich & Rosati PC's mergers and acquisitions practice for five years, Goodwin announced on Wednesday.

  • April 01, 2026

    7th Circ. Says Ill. BIPA Amendment Applies Retroactively

    The Seventh Circuit held Wednesday that a liability-limiting amendment to Illinois' biometric privacy law applies to every lawsuit pending at the time the amendment took effect, ruling that the amendment is only a procedural change to the law and, therefore, must be applied retroactively.

  • April 01, 2026

    Berkshire Must Defend Trulieve In Worker Death Suit

    An insurance company that is a unit of Berkshire Hathaway had an obligation to defend Trulieve Inc. against a Massachusetts wrongful death lawsuit brought by the family of a cannabis worker, a Florida federal judge has ruled, rejecting arguments that the worker wasn't an employee.

  • April 01, 2026

    3 Federal Circuit Clashes To Watch In April

    The Federal Circuit argument calendar for this month includes Centripetal Networks' appeal of a decision clearing Cisco of infringing cybersecurity patents after a multibillion-dollar award was thrown out, as well as Ecobee's challenge to an $11.5 million infringement verdict involving smart thermostats.

  • April 01, 2026

    DC Cannabis Co. Sues Firm Over Botched Grow Facility

    A cannabis industry-focused engineering firm reneged on a promise to build a fully operational indoor grow facility for a D.C.-based medical dispensary, the company told a D.C. federal court, claiming it is now stuck with the unfinished project and $1 million in specialized equipment that can't be resold.

  • April 01, 2026

    Harvard Researcher Can Get Docs On Prosecution Motives

    A Massachusetts federal judge ruled Wednesday that a Harvard Medical School researcher and Russian national charged with smuggling frog embryo specimens can see emails and other documents regarding the government's decision to prosecute her, citing evidence the case was "vindictive."

  • April 01, 2026

    Astellas Beats $115M Milestone Claim In Del. Chancery Ruling

    A Delaware Court of Chancery judge has ruled that Astellas Pharma Inc. is not obligated to pay up to $115 million in disputed drug development milestone payments tied to its acquisition of Potenza Therapeutics Inc., finding that the clinical trials at issue never met the contract's definition of a Phase II study.

  • April 01, 2026

    Mass. Cannabis Businesses Say Repeal Bid Misleads Voters

    A coalition of Massachusetts cannabis business owners Wednesday challenged the constitutionality of a proposal to repeal retail marijuana legalization at the ballot box this November.

  • April 01, 2026

    PBM Opioid Crisis Suit Stays In Federal Court, Judge Says

    A Michigan federal judge on Tuesday denied a request from the state attorney general to remand to state court a suit accusing two pharmacy benefit managers of fueling the opioid crisis, saying the case will remain in federal court because work performed for federal and nonfederal clients cannot be separated.

Expert Analysis

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.